Thiosemicarbazone derivatives: Evaluation as cruzipain inhibitors and molecular modeling study of complexes with cruzain

Bioorg Med Chem. 2022 May 1:61:116708. doi: 10.1016/j.bmc.2022.116708. Epub 2022 Mar 16.

Abstract

The development of cruzipain inhibitors represents one of the most attractive challenges in the search for drugs for the treatment of Chagas disease. A recombinant form of this enzyme, cruzain, has been crystallized with numerous inhibitors, excluding thiosemicarbazones. These compounds have been established as potent inhibitors of cruzain, although there is very little data in the literature of thiosemicarbazones tested on cruzipain. In this work, we present the results of the evaluation of eleven thiosemicarbazones on cruzipain, isolated from T. cruzi epimastigotes, six of them previously evaluated on cruzain. For these latter, we studied through computational methods, the mode of interaction with the active site of cruzain and the contribution of geometric parameters to the possible mechanism of action involved in the observed inhibition. Finally, from some geometric parameters analyzed on modeled TSC-cruzain complexes, a semi-quantitative relationship was established that could explain the inhibitory activity of thiosemicarbazones on cruzipain, the enzyme actually present in the parasite.

Keywords: Chagas Disease; Cruzipain Inhibitors; Molecular Docking; Thiosemicarbazones.

MeSH terms

  • Chagas Disease* / drug therapy
  • Cysteine Endopeptidases / chemistry
  • Cysteine Proteinase Inhibitors / pharmacology
  • Protozoan Proteins
  • Thiosemicarbazones* / chemistry
  • Thiosemicarbazones* / pharmacology
  • Trypanosoma cruzi*

Substances

  • Cysteine Proteinase Inhibitors
  • Protozoan Proteins
  • Thiosemicarbazones
  • Cysteine Endopeptidases
  • cruzipain